Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 10/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 10/20 | 0.38 |
| ▸ | GSK3B | P49841 | 3/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.38 |
| ▸ | WNT1 | P04628 | 2/20 | 0.38 |
| ▸ | IDO1 | P14902 | 2/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | DHFR | P00374 | 1/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | TRPC5 | Q9UL62 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30603338 | 1.00 | SLC6A2 (0.38) | SLC6A2SLC6A4GSK3BDYRK1AWNT1 | |
| Hydrochloric Acid SCHEMBL28682527 | 0.99 | IDO1 (0.38) | SLC6A2SLC6A4GSK3BDYRK1AWNT1 | |
| SCHEMBL24176754 | 0.92 | SLC6A2 (0.38) | SLC6A2SLC6A4GSK3BDYRK1AWNT1 | |
| SCHEMBL29833333 | 0.90 | SLC6A2 (0.40) | SLC6A2SLC6A4IDO1SLC6A3DHFR | |
| SCHEMBL24177156 | 0.90 | SLC6A2 (0.40) | SLC6A2SLC6A4IDO1SLC6A3DHFR | |
| SCHEMBL24176683 | 0.89 | TACR1 (0.40) | SLC6A4GSK3BDYRK1AWNT1EPHX2 | |
| SCHEMBL26019983 | 0.88 | HTR2C (0.33) | SLC6A2SLC6A4GSK3BDYRK1AWNT1 | |
| SCHEMBL24176694 | 0.86 | SLC6A2 (0.43) | SLC6A2SLC6A4SLC6A3EPHX2 | |
| SCHEMBL30866292 | 0.86 | SLC6A2 (0.43) | SLC6A2SLC6A4SLC6A3EPHX2 | |
| SCHEMBL24176792 | 0.86 | DDR1 (0.37) | GSK3BDYRK1AWNT1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240317755-A1 | HETEROCYCLIC COMPOUND, AND INTERMEDIATE THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2024-09-26 | — | — | US | disclosed |
| CN-114907408-B | Heterocyclic compound, intermediate thereof, preparation method and application thereof | 武汉朗来科技发展有限公司 | 2024-05-03 | — | — | CN | disclosed |
| EP-4289846-A1 | HETEROCYCLIC COMPOUND, AND INTERMEDIATE THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | Wuhan LL Science and Technology Development Co., Ltd. (CN) | 2023-12-13 | — | — | EP | disclosed |
| EP-4289846-A1 | HETEROCYCLIC COMPOUND, AND INTERMEDIATE THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | Wuhan LL Science and Technology Development Co., Ltd. (CN) | 2023-12-13 | — | — | EP | disclosed |
| CN-116731013-A | Heterocyclic compound, preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2023-09-12 | — | — | CN | disclosed |
| US-20230257382-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2023-08-17 | — | — | US | disclosed |
| US-20230257382-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2023-08-17 | — | — | US | disclosed |
| CN-114907408-A | Heterocyclic compound, intermediate thereof, preparation method and application thereof | 武汉朗来科技发展有限公司 | 2022-08-16 | — | — | CN | disclosed |
| WO-2022166817-A1 | HETEROCYCLIC COMPOUND, AND INTERMEDIATE THEREOF, PREPARATION METHOD THERFOR AND USE THEREOF | 武汉朗来科技发展有限公司 | 2022-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257382-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TRPC5, TRPC1, GOT1 | SLC6A2 576/4885SLC6A4 208/4885GSK3B 2550/4885 |
| US-20240317755-A1 | HETEROCYCLIC COMPOUND, AND INTERMEDIATE THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | CYP4A11, CYP4F11, CYP51A1 | SLC6A2 421/4885SLC6A4 350/4885GSK3B 650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.